DK3450553T3 - Mrna-terapi til behandling af øjensygdomme - Google Patents

Mrna-terapi til behandling af øjensygdomme Download PDF

Info

Publication number
DK3450553T3
DK3450553T3 DK18201321.9T DK18201321T DK3450553T3 DK 3450553 T3 DK3450553 T3 DK 3450553T3 DK 18201321 T DK18201321 T DK 18201321T DK 3450553 T3 DK3450553 T3 DK 3450553T3
Authority
DK
Denmark
Prior art keywords
treatment
eye diseases
mrna therapy
mrna
therapy
Prior art date
Application number
DK18201321.9T
Other languages
English (en)
Inventor
Pericles Calias
Frank Derosa
Michael Heartlein
Original Assignee
Translate Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54196241&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3450553(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Translate Bio Inc filed Critical Translate Bio Inc
Application granted granted Critical
Publication of DK3450553T3 publication Critical patent/DK3450553T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Dispersion Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK18201321.9T 2014-03-24 2015-03-19 Mrna-terapi til behandling af øjensygdomme DK3450553T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461969483P 2014-03-24 2014-03-24
EP15767977.0A EP3122878B1 (en) 2014-03-24 2015-03-19 Mrna therapy for the treatment of ocular diseases

Publications (1)

Publication Number Publication Date
DK3450553T3 true DK3450553T3 (da) 2020-02-10

Family

ID=54196241

Family Applications (2)

Application Number Title Priority Date Filing Date
DK15767977.0T DK3122878T3 (da) 2014-03-24 2015-03-19 Mrna-terapi til behandling af øjensygdomme
DK18201321.9T DK3450553T3 (da) 2014-03-24 2015-03-19 Mrna-terapi til behandling af øjensygdomme

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK15767977.0T DK3122878T3 (da) 2014-03-24 2015-03-19 Mrna-terapi til behandling af øjensygdomme

Country Status (15)

Country Link
US (2) US20170143848A1 (da)
EP (3) EP3122878B1 (da)
CY (1) CY1121348T1 (da)
DK (2) DK3122878T3 (da)
ES (2) ES2707969T3 (da)
HR (1) HRP20190117T1 (da)
HU (1) HUE041940T2 (da)
LT (1) LT3122878T (da)
ME (1) ME03314B (da)
PL (1) PL3122878T3 (da)
PT (1) PT3122878T (da)
RS (1) RS58337B1 (da)
SI (1) SI3122878T1 (da)
TR (1) TR201900649T4 (da)
WO (1) WO2015148247A1 (da)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2506857T3 (da) 2009-12-01 2018-05-07 Translate Bio Inc Levering af mrna til forstærkning af proteiner og enzymer i human-genetiske sygdomme
EP3674292B1 (en) 2011-06-08 2024-04-10 Translate Bio, Inc. Cleavable lipids
CA2853829C (en) 2011-07-22 2023-09-26 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
MX2016004249A (es) 2013-10-03 2016-11-08 Moderna Therapeutics Inc Polinulcleotidos que codifican el receptor de lipoproteina de baja densidad.
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
EP4079847A1 (en) 2014-07-30 2022-10-26 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
MA46316A (fr) 2015-10-22 2021-03-24 Modernatx Inc Vaccin contre le cytomégalovirus humain
IL258821B (en) 2015-10-23 2022-07-01 Harvard College Nucleobase editors and their uses
CA3007955A1 (en) * 2015-12-10 2017-06-15 Modernatx, Inc. Lipid nanoparticles for delivery of therapeutic agents
CN108712911A (zh) 2015-12-30 2018-10-26 科达制药股份有限公司 抗体及其缀合物
US20210206818A1 (en) 2016-01-22 2021-07-08 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
US20190167811A1 (en) 2016-04-13 2019-06-06 Modernatx, Inc. Lipid compositions and their uses for intratumoral polynucleotide delivery
KR102547316B1 (ko) 2016-08-03 2023-06-23 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 아데노신 핵염기 편집제 및 그의 용도
AU2017308889B2 (en) 2016-08-09 2023-11-09 President And Fellows Of Harvard College Programmable Cas9-recombinase fusion proteins and uses thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
GB2573062A (en) 2016-10-14 2019-10-23 Harvard College AAV delivery of nucleobase editors
WO2018075980A1 (en) 2016-10-21 2018-04-26 Modernatx, Inc. Human cytomegalovirus vaccine
WO2018098312A2 (en) * 2016-11-23 2018-05-31 Mayo Foundation For Medical Education And Research Particle-mediated delivery of biologics
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
DK3585892T3 (da) 2017-02-27 2022-08-22 Translate Bio Inc Fremgangsmåder til oprensning af messenger-rna
EP3585891B1 (en) 2017-02-27 2021-10-27 Translate Bio, Inc. Methods for purification of messenger rna
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
US11542496B2 (en) 2017-03-10 2023-01-03 President And Fellows Of Harvard College Cytosine to guanine base editor
KR102687373B1 (ko) 2017-03-23 2024-07-23 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제
WO2018209320A1 (en) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
JP7285220B2 (ja) 2017-05-18 2023-06-01 モデルナティエックス インコーポレイテッド 連結したインターロイキン－１２（ｉｌ１２）ポリペプチドをコードするポリヌクレオチドを含む脂質ナノ粒子
CN111801345A (zh) 2017-07-28 2020-10-20 哈佛大学的校长及成员们 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
US20190300856A1 (en) * 2017-08-16 2019-10-03 Georgia Tech Research Corporation Messenger RNA based expression of opsins and reporter proteins for electrophysiologic characterization of in vitro neurons and cardiomyocytes
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
US11795443B2 (en) 2017-10-16 2023-10-24 The Broad Institute, Inc. Uses of adenosine base editors
US20210000879A1 (en) * 2018-03-01 2021-01-07 Georgia Tech Research Corporation Methods and compositions for mrna-based modulation and detection of cell phenotypes
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
WO2019240946A1 (en) 2018-06-11 2019-12-19 The Regents Of The University Of California Demethylation to treat eye disease
US11174500B2 (en) 2018-08-24 2021-11-16 Translate Bio, Inc. Methods for purification of messenger RNA
JP7425066B2 (ja) 2018-09-04 2024-01-30 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 核酸を臓器特異的送達するための組成物および方法
GB2617429B (en) 2018-09-04 2023-12-27 Univ Texas Compositions and methods for organ specific delivery of nucleic acids
PL3864163T3 (pl) 2018-10-09 2024-05-20 The University Of British Columbia Kompozycje i układy zawierające pęcherzyki zdolne do transfekcji wolne od rozpuszczalników organicznych i detergentów oraz związane z nimi sposoby postępowania
AU2019376004A1 (en) 2018-11-08 2021-05-13 Translate Bio, Inc. Methods and compositions for messenger RNA purification
US20220016265A1 (en) * 2018-11-09 2022-01-20 Translate Bio, Inc. Messenger rna therapy for treatment of ocular diseases
WO2020146344A1 (en) * 2019-01-07 2020-07-16 Translate Bio, Inc. Composition and methods for treatment of primary ciliary dyskinesia
EP3920950A1 (en) * 2019-02-08 2021-12-15 CureVac AG Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases
JP2022526908A (ja) 2019-03-19 2022-05-27 ザ ブロード インスティテュート，インコーポレーテッド 編集ヌクレオチド配列を編集するための方法および組成物
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
AU2021267940A1 (en) 2020-05-08 2022-12-08 President And Fellows Of Harvard College Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
US11771652B2 (en) 2020-11-06 2023-10-03 Sanofi Lipid nanoparticles for delivering mRNA vaccines
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same
US20240209068A1 (en) * 2021-04-01 2024-06-27 Modernatx, Inc. Mucosal expression of antibody structures and isotypes by mrna
IL309505A (en) 2021-09-03 2024-02-01 CureVac SE Lipid nanoparticles for nucleic acid delivery
WO2023073228A1 (en) 2021-10-29 2023-05-04 CureVac SE Improved circular rna for expressing therapeutic proteins
WO2023077148A1 (en) 2021-11-01 2023-05-04 Tome Biosciences, Inc. Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo
IL313765A (en) 2021-12-22 2024-08-01 Tome Biosciences Inc Joint provision of a gene editor structure and a donor template
WO2023144330A1 (en) 2022-01-28 2023-08-03 CureVac SE Nucleic acid encoded transcription factor inhibitors
WO2023205744A1 (en) 2022-04-20 2023-10-26 Tome Biosciences, Inc. Programmable gene insertion compositions
WO2023215831A1 (en) 2022-05-04 2023-11-09 Tome Biosciences, Inc. Guide rna compositions for programmable gene insertion
WO2023225670A2 (en) 2022-05-20 2023-11-23 Tome Biosciences, Inc. Ex vivo programmable gene insertion
WO2023227608A1 (en) 2022-05-25 2023-11-30 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
WO2024020587A2 (en) 2022-07-22 2024-01-25 Tome Biosciences, Inc. Pleiopluripotent stem cell programmable gene insertion
WO2024089638A1 (en) 2022-10-28 2024-05-02 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine
WO2024138194A1 (en) 2022-12-22 2024-06-27 Tome Biosciences, Inc. Platforms, compositions, and methods for in vivo programmable gene insertion

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4500707A (en) 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US5132418A (en) 1980-02-29 1992-07-21 University Patents, Inc. Process for preparing polynucleotides
US4973679A (en) 1981-03-27 1990-11-27 University Patents, Inc. Process for oligonucleo tide synthesis using phosphormidite intermediates
US4415732A (en) 1981-03-27 1983-11-15 University Patents, Inc. Phosphoramidite compounds and processes
US4668777A (en) 1981-03-27 1987-05-26 University Patents, Inc. Phosphoramidite nucleoside compounds
US4373071A (en) 1981-04-30 1983-02-08 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US4401796A (en) 1981-04-30 1983-08-30 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US5153319A (en) 1986-03-31 1992-10-06 University Patents, Inc. Process for preparing polynucleotides
US5047524A (en) 1988-12-21 1991-09-10 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5262530A (en) 1988-12-21 1993-11-16 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
FR2645866B1 (fr) 1989-04-17 1991-07-05 Centre Nat Rech Scient Nouvelles lipopolyamines, leur preparation et leur emploi
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5700642A (en) 1995-05-22 1997-12-23 Sri International Oligonucleotide sizing using immobilized cleavable primers
US5744335A (en) 1995-09-19 1998-04-28 Mirus Corporation Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
CA2304982A1 (en) * 1997-09-19 1999-03-25 Sequitur, Inc. Sense mrna therapy
US7507859B2 (en) * 2003-06-16 2009-03-24 Fifth Base Llc Functional synthetic molecules and macromolecules for gene delivery
AU2005252273B2 (en) 2004-06-07 2011-04-28 Arbutus Biopharma Corporation Lipid encapsulated interfering RNA
MX2007012766A (es) * 2005-04-12 2008-10-01 Intradigm Corp Composición y métodos de terapéuticos de arni para el tratamiento de cáncer y otras enfermedades de neovascularización.
EP2266656B1 (en) 2005-04-18 2020-10-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Devices for delivering a biologically active agent to the ocular sphere of a subject
WO2008016473A2 (en) 2006-07-28 2008-02-07 Applera Corporation Dinucleotide mrna cap analogs
DE102007001370A1 (de) * 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
US20090011040A1 (en) * 2007-05-02 2009-01-08 Naash Muna I Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
WO2009058911A2 (en) 2007-10-31 2009-05-07 Applied Biosystems Inc. Preparation and isolation of 5' capped mrna
US9139554B2 (en) 2008-10-09 2015-09-22 Tekmira Pharmaceuticals Corporation Amino lipids and methods for the delivery of nucleic acids
AU2009311667B2 (en) 2008-11-07 2016-04-14 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
DK2506857T3 (da) 2009-12-01 2018-05-07 Translate Bio Inc Levering af mrna til forstærkning af proteiner og enzymer i human-genetiske sygdomme
EP2538929A4 (en) 2010-02-25 2014-07-09 Univ Johns Hopkins PROLONGED DELIVERY OF THERAPEUTIC AGENTS TO AN OCULAR COMPARTMENT
US9019345B2 (en) 2010-07-02 2015-04-28 Intuitive Surgical Operations, Inc. Imaging mode blooming suppression
US8853377B2 (en) * 2010-11-30 2014-10-07 Shire Human Genetic Therapies, Inc. mRNA for use in treatment of human genetic diseases
ES2385080B1 (es) 2010-12-21 2013-05-10 Universidad Del Pais Vasco-Euskal Herriko Unibertsitatea Nanopartículas lipídicas para el tratamiento de enfermedades oculares.
JP6184945B2 (ja) * 2011-06-08 2017-08-23 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド ｍＲＮＡ送達のための脂質ナノ粒子組成物および方法
EP3674292B1 (en) 2011-06-08 2024-04-10 Translate Bio, Inc. Cleavable lipids
UA119028C2 (uk) * 2011-10-27 2019-04-25 Массачусеттс Інстітьют Оф Текнолоджі Функціоналізовані на n-кінці амінокислотні похідні, здатні утворювати мікросфери, що інкапсулюють лікарський засіб
PT2791160T (pt) * 2011-12-16 2022-07-04 Modernatx Inc Composições arnm modificado
EP2607375A1 (en) 2011-12-21 2013-06-26 The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin Variants of yeast NDI1 gene, and uses thereof in the treatment of disease associated with mitochondrial dysfunction.
CN104487055A (zh) * 2012-03-29 2015-04-01 夏尔人类遗传性治疗公司 脂质衍生的中性纳米颗粒
CN104334161A (zh) * 2012-03-29 2015-02-04 夏尔人类遗传性治疗公司 可电离的阳离子脂质
JP6189415B2 (ja) * 2012-04-02 2017-08-30 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 細胞質および細胞骨格タンパク質の産生のための修飾ポリヌクレオチド
TWI775096B (zh) * 2012-05-15 2022-08-21 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
US10087247B2 (en) * 2013-03-14 2018-10-02 Translate Bio, Inc. Methods and compositions for delivering mRNA coded antibodies
BR112016009014B1 (pt) * 2013-10-22 2024-02-06 Translate Bio, Inc USO DE COMPOSIÇÃO COMPREENDENDO mRNA PARA DEFICIÊNCIA DE ARGININOSSUCINATO SINTETASE
EA201690576A1 (ru) * 2013-10-22 2016-10-31 Шир Хьюман Дженетик Терапис, Инк. Липидные композиции для доставки матричной рнк
EP3060258A1 (en) * 2013-10-22 2016-08-31 Shire Human Genetic Therapies, Inc. Mrna therapy for phenylketonuria

Also Published As

Publication number Publication date
EP3122878A1 (en) 2017-02-01
RS58337B1 (sr) 2019-03-29
EP3699274A1 (en) 2020-08-26
HRP20190117T1 (hr) 2019-04-19
CY1121348T1 (el) 2020-05-29
HUE041940T2 (hu) 2019-06-28
US20170143848A1 (en) 2017-05-25
EP3122878A4 (en) 2017-08-30
EP3450553A1 (en) 2019-03-06
SI3122878T1 (sl) 2019-05-31
US20220354968A1 (en) 2022-11-10
EP3450553B1 (en) 2019-12-25
DK3122878T3 (da) 2019-02-04
ES2774552T3 (es) 2020-07-21
PT3122878T (pt) 2019-02-01
ES2707969T3 (es) 2019-04-08
TR201900649T4 (tr) 2019-02-21
LT3122878T (lt) 2019-02-11
EP3122878B1 (en) 2018-10-24
WO2015148247A1 (en) 2015-10-01
ME03314B (me) 2019-10-20
PL3122878T3 (pl) 2019-06-28

Similar Documents

Publication Publication Date Title
DK3450553T3 (da) Mrna-terapi til behandling af øjensygdomme
DK3212233T3 (da) Kombinationsterapi til behandling af sygdom
HK1246179A1 (zh) 治療視網膜疾病的方法
DK3448999T3 (da) Oligonukleotider til behandling af øjensygdom
DK3851537T3 (da) Behandling af hyperbilirubinæmi
DK3171928T3 (da) Stimulationsmønstre til behandling af tørt øje
DK3777855T3 (da) Fremgangsmåder til behandling af fibrotiske sygdomme
DK3169328T3 (da) Quinolinderivater til behandling af inflammationssygdomme
DK3362066T3 (da) Kombinationsterapi til behandling af maligniteter
DK3390390T3 (da) Bipyrazolylderivater egnede til behandling af autoimmunsygdomme
DK3142664T3 (da) Sammensætninger og fremgangsmåder til behandling og diagnosticering af øjensygdomme
DK3164394T3 (da) Gls1-inhibitorer til behandling af sygdomme
DK3237621T3 (da) Varianter af human alpha-galactosidase
DK3548061T3 (da) Behandling af neurologiske sygdomme
DK3097085T3 (da) Benzoxazinonderivater til behandling af hudsygdomme
DK3210973T3 (da) Heteroarylforbindelser til behandling af oftalmiske sygdomme
HK1258994A1 (zh) 用於疾病治療的方法
DK3297619T3 (da) Terapeutiske anvendelser af L-4-chlorkynurenin
DK3209295T4 (da) Fremgangsmåder til behandling af øjenlidelser
DK3448388T3 (da) Dipeptidyl-peptidase-4-inhibitorer til topikal øjenbehandling af retinale neurodegenerative sygdomme
DK3229811T3 (da) Forebyggelse og behandling af betændelseslidelser
DK3200783T3 (da) Behandling af erytromelalgi
HK1246679A1 (zh) 絲蟲病的治療
HK1243937A1 (zh) 治療疾病的方法
DK3377061T3 (da) Mirabegron til behandling af nethindesygdomme